Viridian Therapeutics, Inc. (VRDN)
16.30
+0.57
(+3.62%)
USD |
NASDAQ |
Jun 09, 16:00
16.39
+0.09
(+0.55%)
After-Hours: 20:00
Viridian Therapeutics Research and Development Expense (Quarterly) : 77.51M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Amgen, Inc. | 1.719B |
| Spyre Therapeutics, Inc. | 60.41M |
| Praxis Precision Medicines, Inc. | 77.99M |
| CAMP4 Therapeutics Corp. | 9.64M |
| Savara, Inc. | 23.40M |